Test Results of the Effects of Silver Antimicrobial Dressings on Drug Resistant Bacteria *in vitro*

Smith+Nephew

ACTICOAT◊
Antimicrobial Barrier Dressings

Brand name	Product types available	Log reduction in 30 minutes for MRSA	Log reduction in 30 minutes for VRE	Log reduction in 30 minutes for 5 NDM-1 producing bacterial strains	Log reduction in 30 minutes for drug resistant P. *aeruginosa* 137366	Method of silver delivery		What does that mean?
						Initial	Solution (concentration)	
ACTICOAT◊ Antimicrobial Barrier Dressing (Smith+Nephew)	Dressing (3 and 7 day)	>6.0[1]	>6.0[1]	>4.0[7]	>5.0[8]	Silver Ag° Nanocrystals[10]	Ag^+, Ag^0/ Ag^+ clusters (70-100 ppm)[10]	ACTICOAT dressng showed marked bactericidal activity against MRSA, VRE, NDM-1 producing bacterial strains and drug-resistant P. aeruginosa at 30 minutes (*in vitro*)
Silverlon™ (Argentum LLC)	Dressing, island dressing,foam strips (7 day)	0.0[1]	1.54[1]	Not reported	<1[8]	Silver oxide[11]	Ag^+ (<1 ppm)[11]	Silverlon showed no activity against MRSA and bacteriostatic activity against VRE within 30 minutes. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
AQUACEL™ Ag (ConvaTec)	Dressing, rope (7 Day)	0.0[1]	0.0[1]	Not reported	<1[8]	AgCl[11]	Ag^+ (<1-3 ppm)[1a]	Aquacel Ag showed no activity against either MRSA or VRE within 30 minutes. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
Aquacel™ Ag ExtraTM (ConvaTec)	Dressing (7 Days)	<1[2]	<1[2]	Not reported	0.0[2]	AgCl[11]	Ag^+ (<1-3 ppm)[1]	Aquacel Ag Extra showed no activity against either MRSA or VRE within 30 minutes. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
TheraBond 3D™	Wound layer, island, wrap dressing(7 day)	0.0[3]	No Speed of kill data	Not reported	<1[3]	Silver plated fabric	Ag^+ Not reported	Therabond 3D demonstrated bactericidal activity against MRSA, but no rapid activity against VRE was reported. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
KerraContact™ (Crawford Healthcare)	Barrier dressing (7 day)	0.0[4]	0.0[4]	Not reported	Not reported	Silveroxysalts[12]	Ag+, Ag+2, Ag3+ (6 ppm)[12,13]	KerraContact is bactericidal against MRSA or VRE from 4 hours with no effect at 30 minutes reported. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
Mepilex™ Ag (Mölnlycke)	Foam, post-op border, transfer (7 day)	<1[5]	<1[6]	Not reported	<1[9]	Silver sulphate[14]	Ag+ (6 ppm)[15,16]	Mepilex Ag showed no activity against MRSA or VRE in 30 minutes. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
Silvercel™ (Systagenix)	Dressing, rope (7 day)	<1[6]	0.0[6]	Not reported	Not reported	Ag alginate[17]	Ag+ (~1 ppm)[11]	Silvercel showed no activity against MRSA or VRE in 30 minutes. No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*
SilvaSorb™ (Medline Ind.)	Sheet, perforated sheet, strands, (7 day), gel(3 day)	0.0[1]	0.0[1]	Not reported	<1[8]	AgCl[11]	Ag+ (~1 ppm)[11]	SilvaSorb showed no activity against MRSA or VRE in 30 minutes No published data to support rapid antimicrobial activity against NDM-1 producing bacterial strains or drug-resistant P. *aeruginosa*

The Minimum Bactericidal Concentration (MBC) for clinically relevant bacteria is between 5 and >50ppm[18,19] and up to 60.5ppm for MRSA20. This means in order to kill MRSA the dressing must kill bacteria with a MBC of at least 60.5 PPM (200ppm x 0.0325=60.5ppm). Notes: In vitro results do not necessarily translate into clinically relevant results. Antimicrobial agents are considered bactericidal if they induce a 3 or greater log reduction in a clinically relevant timeframe[19] These results do not represent a head-to-head safety/efficacy clinical comparison.

Test Results of the Effects of Silver Antimicrobial Dressings on Drug Resistant Bacteria *in vitro*

Smith+Nephew

ACTICOAT◊
Antimicrobial Barrier Dressings

For detailed product information, including indications for use, contraindications, effects, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use.

References

1. Data on file: Testing performed by Hoosier Microbiological Laboratory, Muncie, IN (independent lab). January 3, 2005.
2. Data on file: 1405007. Antimicrobial activity of DURAFIBER™, DURAFIBER Ag, Aquacel™ Extra, Aquacel Ag Extra and Aquacel Ag+ Extra against bacteria, yeast and fungi commonly found in wounds over a 7 day period.
3. Data on file: 0911020. Antimicrobial assessment of ACTICOAT™ Flex 7 in comparison to Therabond™ against MRSA and Pseudomonas aeruginosa, 2009.
4. Exsalt™ SD7-4 Brochure. PR-0045.0.5.Data on file: 070805
5. Antimicrobial activity of ALLEVYN™ Ag Dressings in comparison to other silver-based antimicrobial dressings against MRSA using a dynamicshake flask method, 2007.
6. Data on file: Testing performed by Hoosier Microbiological Laboratory, Muncie, IN (independent lab). Raw data/XL file.
7. Hope R, et al. The in vitro antibacterial activity of Nanocrystalline Silver dressings against bacteria with NDM-1 carbapenemase [poster]. EWMA; 2012.
8. Data on file: Testing performed by Hoosier Microbiological Laboratory, Muncie, IN (independent lab). January 4, 2005.
9. Data on file: 0707051. Antimicrobial activity of ALLEVYN Ag Dressings in comparison to other silver-based antimicrobial dressings against Pseudomonas aeruginosausing a dynamic shake flask method, 2007.
10. Dunn K, et al. The role of ACTICOAT with Nanocrystalline Silver in the management of burns. Burns. 2004; 30 Suppl 1:S1-9.
11. Ovington LG. Why is Nanocrystalline Silver Superior? WOUNDS. 2004; 13(2):1-9.
12. Exsalt SD7-4 Brochure. PR-0046.0.
13. Djokić N, et al. Coating of High Density Polyethylene (HDPE) with Silver Compounds and Their Antimicrobial Activity in vitro. ECS Transactions. 2008; 11(21):59-68.
14. Mepilex™ Ag 510k (K071354).
15. Schwarzkopf A, et al. "The Release of Silver Ions from Foam Dressings". Wound Management. 2010; 4(1): 1-4.
16. Mepilex Ag European Patent Application: 07004275.9.
17. Silvercel™ Brochure. AWC-SC001.
18. Yin, H.Q. et al. Comparative Evaluation of the Antimicrobial Activity of ACTICOAT Antimicrobial Barrier Dressing. J Burn Care Rehabil 1999;20:195-200.
19. Hall, R.E. et al. Inhibitory and Cidal Antimicrobial Actions of Electrically Generated Silver Ions. J Oral Maxillofac Surg 1987;45:779-784.
20. Maple, P.A. et al. Comparison of the in vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 1992;29:661-668.

Advanced Wound Management
Smith & Nephew
Fort Worth, TX 76109
USA
T +1 (800) 876 1261
F +1 (727) 392 6914

www.smith-nephew.com

ACPE8-32565-1022